NCT05067725

Brief Summary

Between January 2020 to August 2021, fifty percent of patients referred from Geisinger's primary care sites to Neurology for headaches did not trial appropriate first line therapy prior to referral, and there was limited access available at Geisinger's Neurology department. This project was initiated to improve patient experience, management of headache, and provider experience as it relates to headache management. Geisinger's Neurology department, pharmacy department, and Community Medicine Service Line (CMSL) sites have collaborated to develop a Headache CarePath (i.e., a best practice alert containing: an EPIC headache assessment, Express Lane for prescriptions, and Ask-a-doc button for Neurology consult) and piloted at 2 CMSL sites (Woodbine, Selinsgrove) to gain some initial feedback. The feedback has been incorporated into best practice alert (BPA) language and criteria. The project team now plans to implement this CarePath to half of CMSL sites first while the other half of CMSL sites will continue to practice the standard of care as of today. The team will evaluate the impact of this CarePath on patient outcomes \[change in Headache Impact Test-6 (HIT-6) scores, change in the frequency of headaches, and change in pain intensity\], emergency department (ED) visits, number of referrals to Neurology for headache, and prescribing of headache medications by comparing the measures in clinics that had the CarePath implemented to those that did not. Patient outcomes will be collected by Geisinger's Survey Core, which will reach out telephonically to patients to ask about the status of their headaches (HIT-6, frequency, intensity of headaches, M-TOQ-5). Other measures will be collected and analyzed using secondary data sources such as electronic health record (EHR) data. The initial implementation is planned for 6-9 months. The findings from this evaluation will help the CarePath team identify any remaining opportunities or guide the direction of its future enhancements of the CarePath tools. The results of this evaluation will be shared with the Geisinger leadership to demonstrate its value to the organization.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
203

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 23, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

October 5, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

December 6, 2021

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 11, 2022

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2023

Completed
Last Updated

December 20, 2023

Status Verified

December 1, 2023

Enrollment Period

8 months

First QC Date

September 23, 2021

Last Update Submit

December 19, 2023

Conditions

Keywords

Clinical care evaluationPrimary care

Outcome Measures

Primary Outcomes (1)

  • Change in Headache Impact Test-6 (HIT-6) score from baseline to follow up

    A global measure of adverse headache impact. The final HIT-6 score is obtained from simple summation of the six items and ranges between 36 and 78, with larger scores reflecting greater impact.

    baseline, 3 months and 6 months post baseline

Secondary Outcomes (5)

  • Change in headache frequency from baseline to follow up

    baseline, 3 months and 6 months post baseline

  • Change in pain intensity score from baseline to follow up

    baseline, 3 months and 6 months post baseline

  • Change in the proportion of patients who received a prescription for headache medication from baseline to follow up

    baseline, 3 months and 6 months post baseline

  • Change in the number of emergency department visits from baseline to follow up

    baseline, 3 months and 6 months post baseline

  • Change in the proportion of patients who received a referral to neurology for headache from baseline to follow up

    baseline, 3 months and 6 months post baseline

Study Arms (2)

Control

NO INTERVENTION

Standard of practice

CarePath Intervention

EXPERIMENTAL

Clinician decision support computer tool that consists of a best practice alert (BPA) embedded with a headache questionnaire, Medication Express Lane (for medication ordering), and Ask-a-doc button (for prompt virtual consultation with a neurologist)

Other: CarePath

Interventions

During an in-clinic patient encounter with a primary care provider (PCP) in any one of the intervention CMSL sites, the BPA is fired when any type of headache or migraine is entered as a diagnosis or chief complaint. The purpose of the headache assessment questionnaire is to assist the PCP in characterizing patients' headache. The Express Lane will help guide PCP decision-making for prescribing medications, lab/image ordering, and referrals. The Ask-a-doc button will provide timely access to a virtual treatment and diagnosis consult with a neurologist.

CarePath Intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients ≥ 18 years of age for whom the Headache BPA fires at the time for their PCP encounter
  • New or returning patients with headache as visit diagnosis or chief complaint for the office visit or telemedicine encounter
  • Have a minimum baseline HIT-6 score of ≥ 50 points OR
  • Headache frequency of ≥ 12 days with headache or migraine complaint in the last 3 months

You may not qualify if:

  • Patients at the pilot sites (i.e., woodbine, selinsgrove)
  • Patients diagnosed with secondary headache disorders (eg, brain tumors) or serious systemic illness (eg, uncontrolled hypertension, hepatic or renal failure, cardiac failure) or acute infectious illness (eg, flu, sinusitis).
  • Patients with headaches as a symptom due to fall/injury
  • Pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Geisinger Clinic

Danville, Pennsylvania, 17822, United States

Location

MeSH Terms

Conditions

Migraine DisordersHeadache

Condition Hierarchy (Ancestors)

Headache Disorders, PrimaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Apoorva Pradhan, BAMS, MPH

    Geisinger Clinic

    PRINCIPAL INVESTIGATOR
  • Eric Wright, PharmD, MPH

    Geisinger Clinic

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Model Details: Prospective cluster randomized control study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Staff Scientist

Study Record Dates

First Submitted

September 23, 2021

First Posted

October 5, 2021

Study Start

December 6, 2021

Primary Completion

August 11, 2022

Study Completion

January 15, 2023

Last Updated

December 20, 2023

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share

Other researchers can request access to data collected from study participants by reaching out to the P.I.

Locations